Drug intelligence / Profile preview

ASCT 01

Development stage: Phase 2
Lead developer: Lifecells
Modality: Stem Cell Therapies → Cell Therapies
Administration: Intra-arterial, Intramuscular

Overview

ASCT 01 is an autologous, bone marrow-derived stem cell therapy developed by Lifecells, LLC for the treatment of critical limb ischemia (CLI). The preparation consists of stem cells harvested from the patient's own bone marrow, which are then processed and administered via intra-arterial infusion and intramuscular injection into the affected limb. The therapeutic objective is to stimulate angiogenesis and improve blood perfusion in patients who have exhausted all conventional medical and surgical revascularization options. By promoting the formation of new collateral blood vessels, the therapy aims to alleviate ischemic pain, facilitate the healing of ulcers, and prevent major limb amputation.

Other names: autologous bone marrow-derived stem cell preparation

Beyond the preview

Go deeper on ASCT 01.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ASCT 01.

Explore the full profile